news
Merck announces results from Phase 2b study of MK-8237, an investigational house dust mite sublingual allergen immunotherapy tablet
Merck (NYSE:MRK), known as MSD outside the United States and…
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting…
